MKI67 and neoplasm: Immunohistochemistry (IHC) analysis revealed that the positive rates of Ki-67 staining in the SHIFT&DOX, TIFT&DOX, lipiodol control and blank groups were 0.79 ± 0.47, 44.89 ± 8.05, 48.55 ± 5.48, 67.94 ± 1.31%, respectively (Figure 7D, G), suggesting the significant inhibition of tumor proliferation with SHIFT&DOX treatment.